Bergstrom Donald A 4

What Happened Donald A. Bergstrom, President of Research & Development at Relay Therapeutics (RLAY), sold 8,660 shares of RLAY in an open-market sale on July 6, 2026. The weighted average sale price reported was $18.71 per share, for aggregate proceeds of $162,029. This was a sale (code S), not a purchase or award.

Key Details

• Transaction date: July 6, 2026; Form 4 filed July 8, 2026 (timely filing).
• Price: weighted average $18.71; individual trade prices ranged $18.45–$19.36 (transaction executed in multiple trades).
• Amount: 8,660 shares sold; total proceeds $162,029.
• Ownership note: filing indicates holdings include 15,037 shares underlying restricted stock units (RSUs).
• Footnotes: sale was made pursuant to a Rule 10b5-1 trading plan adopted Oct 30, 2025; the filer can provide per-trade breakdown on request.

Context This sale was carried out under a pre-established 10b5-1 plan, which is commonly used to schedule insider sales in advance and can reflect routine liquidity needs rather than a change in outlook. Sales are generally less informative than purchases about insider conviction; no exercise of options or gifts were reported in this filing.